211 related articles for article (PubMed ID: 35844005)
1. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.
Ai J; Tan G; Li W; Liu H; Li T; Zhang G; Zhou Z; Gan Y
Cell Biol Toxicol; 2023 Apr; 39(2):537-556. PubMed ID: 35844005
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of EB virus miR-BART4 inhibits proliferation and aggressiveness while promoting radiosensitivity of nasopharyngeal carcinoma.
Wu Q; Han T; Sheng X; Zhang N; Wang P
Biomed Pharmacother; 2018 Dec; 108():741-751. PubMed ID: 30248542
[TBL] [Abstract][Full Text] [Related]
3. Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Liu Y; Jiang Q; Liu X; Lin X; Tang Z; Liu C; Zhou J; Zhao M; Li X; Cheng Z; Li L; Xie Y; Liu Z; Fang W
EBioMedicine; 2019 Oct; 48():386-404. PubMed ID: 31594754
[TBL] [Abstract][Full Text] [Related]
4. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
Lin C; Zong J; Lin W; Wang M; Xu Y; Zhou R; Lin S; Guo Q; Chen H; Ye Y; Zhang B; Pan J
J Exp Clin Cancer Res; 2018 Nov; 37(1):283. PubMed ID: 30477559
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting SOX2.
Li T; Zhang G; Li W; Xiao J; Zhou Z; Tan G; Ai J
Biol Chem; 2023 Sep; 404(10):961-975. PubMed ID: 36752150
[TBL] [Abstract][Full Text] [Related]
6. Nasopharyngeal carcinoma derived exosomes regulate the proliferation and migration of nasopharyngeal carcinoma cells by mediating the miR-99a-5p BAZ2A axis.
Zhou XJ; Xu HM; Huang GS; Lin BR
Braz J Otorhinolaryngol; 2024; 90(1):101343. PubMed ID: 37925811
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus miR-BART4-3p regulates cell proliferation, apoptosis, and migration by targeting AXL in gastric carcinoma.
Zhao MH; Liu W; Zhang Y; Liu JJ; Song H; Luo B
Virus Genes; 2022 Feb; 58(1):23-34. PubMed ID: 35083633
[TBL] [Abstract][Full Text] [Related]
8. CircZNF609 promotes cell proliferation, migration, invasion, and glycolysis in nasopharyngeal carcinoma through regulating HRAS via miR-338-3p.
Liu Z; Liu F; Wang F; Yang X; Guo W
Mol Cell Biochem; 2021 Jan; 476(1):175-186. PubMed ID: 32970285
[TBL] [Abstract][Full Text] [Related]
9. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
10. EBV encoded miRNA BART8-3p promotes radioresistance in nasopharyngeal carcinoma by regulating ATM/ATR signaling pathway.
Zhou X; Zheng J; Tang Y; Lin Y; Wang L; Li Y; Liu C; Wu D; Cai L
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31471531
[TBL] [Abstract][Full Text] [Related]
11. HIF-1α downregulation of miR-433-3p in adipocyte-derived exosomes contributes to NPC progression via targeting SCD1.
Yin H; Qiu X; Shan Y; You B; Xie L; Zhang P; Zhao J; You Y
Cancer Sci; 2021 Apr; 112(4):1457-1470. PubMed ID: 33511729
[TBL] [Abstract][Full Text] [Related]
12. EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC.
Yan Q; Zeng Z; Gong Z; Zhang W; Li X; He B; Song Y; Li Q; Zeng Y; Liao Q; Chen P; Shi L; Fan S; Xiang B; Ma J; Zhou M; Li X; Yang J; Xiong W; Li G
Oncotarget; 2015 Dec; 6(39):41766-82. PubMed ID: 26497204
[TBL] [Abstract][Full Text] [Related]
13. Long Noncoding RNA HOXA11-AS Modulates the Resistance of Nasopharyngeal Carcinoma Cells to Cisplatin via miR-454-3p/c-Met.
Lin FJ; Lin XD; Xu LY; Zhu SQ
Mol Cells; 2020 Oct; 43(10):856-869. PubMed ID: 33115978
[TBL] [Abstract][Full Text] [Related]
14. LncRNA XIST knockdown suppresses the malignancy of human nasopharyngeal carcinoma through XIST/miRNA-148a-3p/ADAM17 pathway in vitro and in vivo.
Shi J; Tan S; Song L; Song L; Wang Y
Biomed Pharmacother; 2020 Jan; 121():109620. PubMed ID: 31810117
[TBL] [Abstract][Full Text] [Related]
15. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.
Lin TY; Jia JS; Luo WR; Lin XL; Xiao SJ; Yang J; Xia JW; Zhou C; Zhou ZH; Lin SJ; Li QW; Yang ZZ; Lei Y; Yang WQ; Shen HF; Huang SH; Wang SC; Chen LB; Yang YL; Xue SW; Li YL; Dai GQ; Zhou Y; Li YC; Wei F; Rong XX; Luo XJ; Zhao BX; Huang WH; Xiao D; Sun Y
J Exp Clin Cancer Res; 2024 Feb; 43(1):62. PubMed ID: 38419081
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA PTPRG-AS1/microRNA-124-3p regulates radiosensitivity of nasopharyngeal carcinoma via the LIM Homeobox 2-dependent Notch pathway through competitive endogenous RNA mechanism.
Shen Z; Wu Y; He G
Bioengineered; 2022 Apr; 13(4):8208-8225. PubMed ID: 35300558
[TBL] [Abstract][Full Text] [Related]
17. MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.
Bissey PA; Teng M; Law JH; Shi W; Bruce JP; Petit V; Tsao SW; Yip KW; Liu FF
BMC Cancer; 2020 Jun; 20(1):597. PubMed ID: 32586280
[TBL] [Abstract][Full Text] [Related]
18. miR-135b-5p Targets SIRT1 to Inhibit Deacetylation of c-JUN and Increase MMP7 Expression to Promote Migration and Invasion of Nasopharyngeal Carcinoma Cells.
Cheng Y
Mol Biotechnol; 2022 Jun; 64(6):693-701. PubMed ID: 35094303
[TBL] [Abstract][Full Text] [Related]
19. microRNA-342-3p targets FOXQ1 to suppress the aggressive phenotype of nasopharyngeal carcinoma cells.
Cui Z; Zhao Y
BMC Cancer; 2019 Jan; 19(1):104. PubMed ID: 30678643
[TBL] [Abstract][Full Text] [Related]
20. Circ_0000523 regulates miR-1184/COL1A1/PI3K/Akt pathway to promote nasopharyngeal carcinoma progression.
Huang P; Li M; Tang Q; Jiang K; Luo Y
Apoptosis; 2022 Oct; 27(9-10):751-761. PubMed ID: 35759163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
